Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Registry-based study of patients treated with exagamglogene autotemcel (exa-cel) in the Kingdom of Saudi Arabia	Vertex	Ongoing	Exagamglogene autotemcel (Casgevy)	4	290-103	-
A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease	Novo Nordisk	Ongoing	Etavopivat	3	NN7535-7807	King Abdulaziz Hospital NG (Al Ahsa), King Faisal Specialist Hospital and Research Center (Riyadh) ,Imam Abdulrahman Al Faisal Hospital NG (Dammam)
Evaluation of safety and efficacy of non-anesthesia provider-administered different anesthetic regimens during colonoscopy: a single center, prospective double blind, randomized study	PI initiated	Ongoing	Propofol	4	6074515	King Saud Hospital (Unaizah)
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia	Vertex / CTI	Ongoing	VX 880	3	VX20-880-101	King Abdulaziz Hospital NG (Riyadh)
Patient and prescriber survey: effectiveness measures to investigate awareness, knowledge, and adherence to the additional risk minimisation measures (aRMM) of the patient reminder card for oral ambrisentan (PrVolibris®)	GSK	Ongoing	Ambrisentan	4	221772	King Abdullah International Medical Research Center– Jeddah
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure	Astrazeneca	Ongoing	Baxdrostat	3	D6972C00002	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam), King Fahad Medical City (Riyadh), King Abdulaziz Hospital NG (Al Ahsa), King Abdulaziz Medical City NG (Riyadh)
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa	AbbVie Biopharmaceuticals GmbH ScientificOffice	Ongoing	Lutikizumab	3	M20-465	King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah)
Real-world evidence Non-Interventional proSpective study of kisqaLi (Ribociclib) Effectiveness and safety in patients with HR+/HER2- early Breast Cancer in Saudi Arabia	Novartis Saudi Ltd	Ongoing	kisqaLi (ribociclib)	2	CLEE011ASA	King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c 2.4 mg Once-weekly	Novo Nordisk	Ongoing	Semaglutide	3	NN9536-7752	King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh) ,King Abdulaziz Hospital NG (Al Ahsa), King Abdulaziz Medical City NG (Jeddah) ,King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II (RAPIDe-2)	Pharvaris Netherlands B.V.	Ongoing	Deucrictibant	2/3	PHA022121-C303	King Faisal Specialist Hospital and Research Center (Riyadh)